Losartan: a pharmacoeconomic review

References

• Trogdon JG, Finkelstein EA, Nwaise IA, et al. The economic burden of chronic cardiovascular disease for major insurers. Health Promotion Practice 2007; 8((3))234–242
   PubMedGoogle Scholar
• Leal J, Luengo-Fernández R, Gray A, et al. Economic burden of cardiovascular diseases in the enlarged European Union. European Heart Journal 2006; 27((13))1610–1619
   PubMed Web of Science ®Google Scholar
• Carides GW, Shahinfar S, Dasbach EJ, et al. The impact of losartan on the lifetime incidence of end-stage renal disease and costs in patients with type 2 diabetes and nephropathy. Pharmacoeconomics 2006; 24((6))549–558
   PubMed Web of Science ®Google Scholar
• Mancia G. Prevention and treatment of stroke in patients with hypertension. Clinical Therapeutics 2004; 26((5))631–648
   PubMed Web of Science ®Google Scholar
• Fjaertoft H, Indredavik B. Cost-estimates for stroke. Tidsskrift for den Norske laegeforening 2007; 127((6))744–747
   PubMedGoogle Scholar
• Kolominsky-Rabas PL, Heuschmann PU, Marschall D, et al. Lifetime cost of ischemic stroke in Germany: results and national projections from a population-based stroke registry: the Erlangen Stroke Project. Stroke 2006; 37((5))1179–1183
   PubMed Web of Science ®Google Scholar
• Herman WH, Shahinfar S, Carides GW, et al. Losartan reduces the costs associated with diabetic end-stage renal disease: the RENAAL study economic evaluation. Diabetes Care 2003; 26((3))683–687
   PubMed Web of Science ®Google Scholar
• Burgess ED, Carides GW, Gerth WC, et al. Losartan reduces the costs associated with nephropathy and end-stage renal disease from type 2 diabetes: Economic evaluation of the RENAAL study from a Canadian perspective. Canadian Journal of Cardiology 2004; 20((6))613–618
   PubMed Web of Science ®Google Scholar
• Szucs TD, Sandoz MS, Keusch GW. The cost-effectiveness of losartan in type 2 diabetics with nephropathy in Switzerland–an analysis of the RENAAL study. Swiss Medical Weekly 2004; 134((31–32))440–447
   PubMed Web of Science ®Google Scholar
• Jönsson L, Carides GW, Burke TA, et al. Cost-effective prevention of renal failure in type 2 diabetics using losartan. Journal of Medical Economics 2005; 8: 131–138
   Google Scholar
• Seng WK, Hwang SJ, Han DC, et al. Losartan reduces the costs of diabetic end-stage renal disease: an Asian perspective. Nephrology (Carlton) 2005; 10((5))520–524
   PubMed Web of Science ®Google Scholar
• Souchet T, Durand Zaleski I, Hannedouche T, et al. An economic evaluation of losartan therapy in type 2 diabetic patients with nephropathy: an analysis of the RENAAL study adapted to France. Diabetes Metabolism 2003; 29((1))29–35
   PubMed Web of Science ®Google Scholar
• Gerth WC, Ribeiro Ab, Ferder LF, et al. Losartan reduces the burden of end-stage renal disease: public health implication from the RENAAL Study for Latin America. Sociedad Iberoamericana de Informacion Cientifica (SIIC). 2005
   Google Scholar
• Gerth WC, Remuzzi G, Viberti G, et al. Losartan reduces the burden and cost of ESRD: public health implications from the RENAAL study for the European Union. Kidney International 2002; 62((Suppl 82))68–72
   Google Scholar
• Arredondo A, Burke TA, Carides GW, et al. The impact of losartan on the lifetime incidence of ESRD and costs in Mexico. Revista de Investigación Clínica 2005; 57((3))399–405
   PubMedGoogle Scholar
• Vora J, Carides GW, Robinson P. Effect of losartan-based therapy on the incidence of end-stage renal disease and associated costs in type diabetes mellitus: a retrospective cost-effectiveness analysis in the United Kingdom. Current Therapetuic Research. 2005
   Google Scholar
• Jönsson B, Carides GW, Burke TA, et al. Cost effectiveness of losartan in patients with hypertension and LVH: an economic evaluation for Sweden of the LIFE trial. Journal of Hypertension 2005; 23((7))1425–1431
   PubMed Web of Science ®Google Scholar
• Keiding H, Hildebrandt P, Burke T, et al. Cost-effectiveness of treatment of high blood pressure with losartan in Denmark [Article in Danish]. Ugeskrift for Laeger 2006; 168((42))3623–3626
   PubMedGoogle Scholar
• McInnes G, Burke TA, Carides G. Cost-effectiveness of losartan-based therapy in patients with hypertension and left ventricular hypertrophy: a UK-based economic evaluation of the Losartan Intervention for Endpoint reduction in hypertension (LIFE) study. Journal of Human Hypertension 2006; 20((1))51–58
   PubMed Web of Science ®Google Scholar
• Boersma C, Carides GW, Atthobari J, et al. An economic assessment of losartan-based therapy in patients with hypertension and left-ventricular hypertrophy: results from the Losartan Intervention For Endpoint reduction (LIFE) Study adapted to the Netherlands. Clinical Therapeutics 2007; 29((5))963–971
   PubMed Web of Science ®Google Scholar
• Anis AH, Sun H, Singh S, et al. A cost-utility analysis of losartan versus atenolol in the treatment of hypertension with left ventricular hypertrophy. Pharmacoeconomics 2006; 24((4))387–400
   PubMed Web of Science ®Google Scholar
• Szucs TD, Burnier M, Erne P. Cost-effectiveness of losartan versus atenolol in treating hypertension–an analysis of the LIFE study from a Swiss perspective. Cardiovascular Drugs Therapy 2004; 18((5))391–397
   PubMed Web of Science ®Google Scholar
• Dasbach EJ, Rich MW, Segal R, et al. The cost-effectiveness of losartan versus captopril in patients with symptomatic heart failure. Cardiology 1999; 91((3))189–194
   PubMed Web of Science ®Google Scholar
• Konstam MA, Neaton JD, Poole-Wilson PA, et al. Comparison of losartan and captopril on heart failure-related outcomes and symptoms from the losartan heart failure survival study (ELITE II). American Heart Journal 2005; 150((1))123–131
   PubMed Web of Science ®Google Scholar
• Drummond MF, Pang F. Transferability of economic evaluation results In:. (Editors). Economic Evaluation in Health Care: Merging Theory with Practice., MF Drummond, A McGuire. Oxford University Press, OxfordUK 2001; 256–276
   Google Scholar